Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
Status:
Completed
Trial end date:
2021-07-15
Target enrollment:
Participant gender:
Summary
This Phase II trial evaluates the safety and immunogenicity of two doses of the Folate
Receptor Alpha (FRĪ±) peptide vaccine mixed with GM-CSF as a vaccine adjuvant, with or without
a immune priming with cyclophosphamide, as a consolidation therapy after neoadjuvant or
adjuvant treatment of patients with Stage IIb-III triple negative breast cancer (TNBC).